Ali Tabarroki

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

Fabı́ola Traina, Valeria Visconte, Paul Elson et al. · Leukemia · 2013 · 283 citations · Full text

Hematological Malignancy, Molecular Mutations, Medicine +7

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy

Reda Z. Mahfouz, Ania Jankowska, Quteba Ebrahem et al. · Clinical Cancer Research · 2013 · 132 citations · Full text

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

Mikkael A. Sekeres, Ramón V. Tiu, Rami S. Komrokji et al. · Blood · 2012 · 131 citations · Full text

Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis

Ali Tabarroki, Daniel J. Lindner, Valeria Visconte et al. · Leukemia · 2014 · 69 citations

Hypertension, Antifibrotic Therapy, Pulmonary Arterial Hypertension +12

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron

Valeria Visconte, Nanthawan Avishai, Reda Z. Mahfouz et al. · Leukemia · 2014 · 61 citations

Hematological Malignancy, Genetic Disorder, Iron Metabolism +10